HM61713
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
